Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors

• US 20040220189A1
• Filed: 02/20/2004
• Published: 11/04/2004
• Est. Priority Date: 02/20/2003
• Status: Active Grant

• Current Assignee: Sugen Incorporated (Pharmacia Corp.)
• Original Assignee: Sugen Incorporated (Pharmacia Corp.)
• Inventors: Liang, Congxin, Huang, Ping, Guan, Huiping, Harris, G. Davis Jr., Sun, Connie Li
• Granted Patent: US 7,157,460 B2
• Time in Patent Office: Days
• US Class Current: 514/249
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Claims

1. A compound of formula I:

5. The compound of claim 1, wherein R₄ and R₅ are optionally substituted aryl.

8. A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

9. A method for the modulation of the catalytic activity of a protein kinase comprising contacting the protein kinase with a compound or a pharmaceutically acceptable salt of a compound claim 1.

10. The method of claim 9, wherein the protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

11. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt of a compound of claim 1 and a pharmaceutically acceptable carrier or excipient to the organism.

12. The method of claim 11, wherein the protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

13. The method of claim 11, the protein kinase related disorder is selected from the group consisting of an PDGFR related disorder and a flk related disorder.

14. The method of claim 11, wherein the protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi'"'"'s sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

15. The method of claim 11, wherein the protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis (including pulmonary fibrosis), psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

16. The method of claim 11, wherein the organism treated is a human.

2. A compound of the formula I:

3. A compound of formula I:

4. A compound of formula I:

6. A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine,

3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,

N-[4-(4-trifluoromethyl-benzamide-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide,

N-[4-(8-Amino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide,

(4-Methoxy-phenyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Isopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Isopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Butyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

(2-Morpholin-4-yl-ethyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Benzyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

2-(3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamino)-ethanol,

1-Butyl-3-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-urea,

N-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

N-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

2,6-Dimethyl-4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,

Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

[3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-[3-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

Methyl-[3-(3-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

Methyl-[3-(2-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

(3-Biphenyl-2-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

[3-(2-Benzyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[3-(3-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(4-tert-Butyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(4-Cyclohexyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,

3-(8-Methylamino-imidazo[1,2-a]pyrazin-4-yl)-benzoic acid,

Methyl-(3-o-tolyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

Methyl-[3-(4-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

[3-(2,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(3,4-Dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

(3-Biphenyl-4-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

(3-Biphenyl-3-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

[3-(4-Benzyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-(3-naphthalen-1-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,

[3-(2-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

N-[3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]acetamide,

Methyl-[3-(2-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

Methyl-[3-(3-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

Cyclopropyl-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,

3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

[3-(2-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(3,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

(3-Benzo[1,3]dioxol-5-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

[3-(3-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(4-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(2-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

[3-(4-Benzyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(4-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,

Cyclopropyl-[3-(3,4-dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,

Methyl-{3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,

Cyclopropyl-{3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,

Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

Cyclopropyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,

[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,

[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,

Methyl-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,

[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)—

N-(2-morpholin-4-yl-ethyl)-benzamide,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)—

N-(3-morpholin-4-yl-propyl)-benzamide,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)—

N-(3-pyrrolidin-1-yl-propyl)-benzamide,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(S)-3-Hydroxy-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

4-Hydroxy-piperidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

4-Hydroxy-piperidine-1-carboxylic acid[3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(R)-2-Dimethylaminomethyl-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

(R)-3-Hydroxy-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

[5-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-(5-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Methyl-(5-thiophen-3-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenol,

N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenyl]-acetamide,

[3,5-Bis-(4-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

(3,5-Diphenyl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

Methyl-(6-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-6-yl)-phenol,

6-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine and

Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-5-yl-amine,

or a prodrug or pharmaceutically acceptable salt thereof.

7. A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

[3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

[3-(4-Benzyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,

[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,

[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,

[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

(S)-3-Hydroxy-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid[3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

4-Hydroxy-piperidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,

(R)-3-Hydroxy-pyrrolidine-1-carboxylic acid[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea and

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

or a prodrug or pharmaceutically acceptable salt thereof.